pharmaphorum| News & views on pharma and biotech’s evolving future

News

CARSgen bags world-first approval for solid tumour CAR-T

CARSgen Therapeutics has claimed approval in China for gastric cancer therapy satri-cel, the first CAR-T to be cleared for a solid tumour.

News

AbbVie climbs post-Allergan M&A peak with Apogee buy

AbbVie has announced its biggest acquisition since the $63 billion merger with Allergan, buying Apogee and its 'mega-blockbuster' immunology pipeline.

Market Access

Direct-to-patient access: Five questions pharma must answer

Patients

Patient engagement drives clinical and commercial success

Engagement solutions can tap into long-lasting patient motivations that sustain behaviour.

Oncology

ASCO 2026 reshapes oncology trial design

The American Society of Clinical Oncology 2026 annual meeting showcased how, across tumour types, new cancer therapies are achieving deeper responses, extending survival and increasingly mo

Featured Content

Patients

Patient engagement drives clinical and commercial success

Engagement solutions can tap into long-lasting patient motivations that sustain behaviour.

Spotlight on

ASCO 2026

As the buzz increases in volume and the clock to kick-off counts down, keep an eye on this Spotlight On page for content coming to you from onsite in Chicago. We’ll have features and video content rolling out as the presentations unfold day by day.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Oncology

pharmaphorum podcast Episode 264, ITM's Dr Andrew Cavey

Radiopharma in 2026 & beyond, with ITM's Dr Andrew Cavey

Dr Andrew Cavey, CEO of ITM, discusses current and future radiopharmaceutical trends.

Oncology

ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o...

For years, ADCs have been positioned as an important addition to the oncology toolkit. But, could they eventually replace chemotherapy altogether?

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

Newsletters and Deep Dive
digital magazine

Latest News

News

CARSgen bags world-first approval for solid tumour CAR-T

CARSgen Therapeutics has claimed approval in China for gastric cancer therapy satri-cel, the first CAR-T to be cleared for a solid tumour.

News

AbbVie climbs post-Allergan M&A peak with Apogee buy

AbbVie has announced its biggest acquisition since the $63 billion merger with Allergan, buying Apogee and its 'mega-blockbuster' immunology pipeline.

News

Boehringer advances duo for aggressive cancers into phase 3

Boehringer Ingelheim steps up its push into oncology with phase 3 trials for pathfinder product Hernexeos and obrixtamig in hard-to-treat cancers.

News

Genpact finds $18tn in trapped AI value

Genpact and analyst firm HFS Research recently published a new global study identifying four enterprise debts.

Views & Analysis

Patients

Patient engagement drives clinical and commercial success

Engagement solutions can tap into long-lasting patient motivations that sustain behaviour.

Oncology

ASCO 2026 reshapes oncology trial design

The American Society of Clinical Oncology 2026 annual meeting showcased how, across tumour types, new cancer therapies are achieving deeper responses, extending survival and increasingly mo

Oncology

Liquid biopsy and the future of tumour-agnostic treatments

Liquid biopsy-based tools are positioned as a critical enabler of tumour-agnostic therapeutic development.

Digital

Google AI Overviews: What it means for pharma

EVERSANA INTOUCH’s 2026 Pharma AI Overviews Report covers the rapid evolution within the Google AI Overviews landscape.

Deep Dive

Market Access

Market Access 2026

Market Access

Five dynasties that built modern pharma

Market Access

MFN and TrumpRx: What’s the real impact for the American con...

Market Access

The expanding role of early-phase trials in modern drug deve...

White Papers & Webinar

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

Digital

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

R&D

From obesity to outcomes abstract visual

Sponsored

The future of cardiometabolic trials: From obesity to outcom...

Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO

R&D

Sponsored

A data-driven guide to small molecule drug discovery and dev...

A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.

Podcasts & Video

Oncology

ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o...

For years, ADCs have been positioned as an important addition to the oncology toolkit. But, could they eventually replace chemotherapy altogether?

Oncology

Radiopharma in 2026 & beyond, with ITM's Dr Andrew Cavey

Dr Andrew Cavey, CEO of ITM, discusses current and future radiopharmaceutical trends.

Oncology

ASCO 2026: Powerful evidence for the microbiome in oncology,...

Can the state of someone’s gut microbiome – the balance of good and bad bacteria in their digestive tract – affect their response to cancer immunother

Patients